Abstract
The aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO IIb to IVa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 mg/m2, and cisplatin was administered weekly with the dosage of 20 mg/m2 during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significnat improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.
Highlights
Cervical cancer is the most common gynecologic cancer
To investigate the early outcome of the Endosta combined with chemoradiotherapy to the advanced cervical cancer. 52 patients with cervical cancer in II b-IV stage, who hospitalized in oncology unit from September 2009 to October 2010, were randomly divided into chemoradiotherapy group and Endostar combined with chemoradiotherapy group
Effect of treatment According to general standard for solid tumor treatment efficacy (Sun and Shi, 2007), the outcome of treatment divided into complete remission (CR), partial remission (PR), stable (NC) and deterioration (PD)
Summary
Cervical cancer is the most common gynecologic cancer. Surgery or radiotherapy can achieve satisfactory effect for early stage cervical cancer, while in the late stage (II b-IV a period) the main treatment therapy is radiation. (Lu et al, 2003; Dubay et al, 2004; Eifel et al, 2004; Rose et al, 2007; Duenas-Gonzale et al, 2011) These trials have shown that the use of Concurrent chemoradiation results in a 30%-50% decrease in the risk of death compared to RT alone. Jia et al (2009) proved endostar can reduce the tumor growth and metastasis by inhibiting angiogenesis and lymphangiogenesis in nude mouse model of human cervical cancer. Endostar combined with chemotherapy is well-tolerated in patients with metastatic colorectal cancer, gastric cancer and advanced non-small cell lung cancer, and it is relatively effective as a first-line therapy (Ge et al, 2011; Han et al, 2011; Li et al, 2011; Zhou et al, 2011).
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call